Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis
Shots:
- NICE has recommended Cosentyx as a cost-effective option for the treatment of mod. to sev. PsO in patients aged 6-17 yrs. who have not responded to other forms of systemic treatment & for whom these options were contraindicated or not tolerated
- Additionally- patients will now have access to this treatment option on the NHS. The therapy is supported through the sustained efficacy and safety data across psoriasis- PsA- and axSpA with 500-000+ patients treated globally
- Secukinumab (SC- q4w) is the first IL-17A inhibitor to be recommended by NICE & is approved in 90+ countries including the UK- in EU- US- Japan & China
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com